First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.

导出 OA

翻译打印收藏纠错

第一作者： Susanna,Hegewisch-Becker

第一单位： Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany.

作者： Susanna,Hegewisch-Becker ^[1] ; Guillermo,Mendez ^[2] ; Joseph,Chao ^[3] ; Radim,Nemecek ^[4] ; Kynan,Feeney ^[5] ; Eric,Van Cutsem ^[6] ; Salah-Eddin,Al-Batran ^[7] ; Wasat,Mansoor ^[8] ; Nicholas,Maisey ^[9] ; Roberto,Pazo Cid ^[10] ; Matthew,Burge ^[11] ; David,Perez-Callejo ^[12] ; R William,Hipkin ^[13] ; Sourav,Mukherjee ^[13] ; Ming,Lei ^[13] ; Hao,Tang ^[13] ; Satyendra,Suryawanshi ^[13] ; Ronan J,Kelly ^[14] ; Niall C,Tebbutt ^[15]

作者单位： Hematology-Oncology Practice Eppendorf (HOPE), Hamburg, Germany. ^[1] Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina. ^[2] City of Hope Comprehensive Cancer Center, Duarte, CA. ^[3] Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic. ^[4] St John of God Murdoch Hospital, Murdoch, WA, Australia. ^[5] University Hospitals Gasthuisberg and University of Leuven (KUL), Leuven, Belgium. ^[6] Krankenhaus Nordwest University Cancer Center Frankfurt, and Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Frankfurt, Germany. ^[7] The Christie NHS Foundation Trust, Manchester, United Kingdom. ^[8] Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom. ^[9] Hospital Miguel Servet, Zaragoza, Spain. ^[10] Royal Brisbane & Womens Hospital, Herston, QLD, Australia. ^[11] Bristol Myers Squibb, Boudry, Switzerland. ^[12] Bristol Myers Squibb, Princeton, NJ. ^[13] Baylor University Medical Center, Dallas, TX. ^[14] Austin Health, Heidelberg, VIC, Australia.;University of Melbourne, Melbourne, VIC, Australia. ^[15]